News
FDA approves new drug for advanced head and neck squamous cell carcinoma
The Brief
- The US Food and Drug Administration (FDA) has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) from Janssen Biotech.
- The approval covers adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease progressed during or after prior treatment.
- The source article is dated 2026-11-18 and reports the approval; the exact approval date is not stated in the available text.
Why it matters
It adds an FDA-approved treatment option for a group of advanced head and neck squamous cell carcinoma patients whose disease has progressed, a setting where options are limited.
Who’s affected
- oncologists and clinicians treating head and neck squamous cell carcinoma
- patients with recurrent or metastatic head and neck squamous cell carcinoma
The U.S. Food and Drug Administration has approved Janssen Biotech's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed during or after receipt…